Literature DB >> 1771651

Trace analysis of methotrexate and 7-hydroxymethotrexate in human plasma and urine by a novel high-performance liquid chromatographic method.

O Beck1, P Seideman, M Wennberg, C Peterson.   

Abstract

A new high-performance liquid chromatographic method for the quantitative determination of methotrexate (MTX) and its metabolite 7-hydroxymethotrexate (7-OHMTX) in blood plasma and urine was developed. The method utilized a solid-phase extraction procedure (Certify II cartridges) for the simultaneous isolation of MTX and 7-OHMTX. Chromatographic separation was achieved using a C18 reversed-phase column with isocratic elution. The eluent was irradiated with UV light of 254 nm, which converted MTX and 7-OHMTX by photolytic oxidation to fluorescent products. The limits of detection of MTX and 7-OHMTX in plasma were approximately 0.2 and 1 nmol/L, respectively. The intraday variability in the quantitation of MTX and 7-OHMTX was less than 8% down to 1 nmol/L and 4.6 nmol/L, respectively. Both MTX and 7-OHMTX could be detected in plasma from a patient being treated for rheumatoid arthritis 1 week after the last dose (10 mg orally).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1771651     DOI: 10.1097/00007691-199111000-00011

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

1.  Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate.

Authors:  U Tröger; B Stötzel; J Martens-Lobenhoffer; H Gollnick; F P Meyer
Journal:  BMJ       Date:  2002-06-22

Review 2.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring of antimetabolic cytotoxic drugs.

Authors:  L Lennard
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

4.  Use of methotrexate in older patients. A risk-benefit assessment.

Authors:  S E Tett; E J Triggs
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

5.  The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis.

Authors:  P Seideman; O Beck; S Eksborg; M Wennberg
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

6.  Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis.

Authors:  Jaroslav Chládek; Jiøí Grim; Jiøina Martínková; Marie Simková; Jaroslava Vanìèková; Vìra Koudelková; Marie Noièková
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

7.  Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry.

Authors:  Ping Guo; Xiaomin Wang; Liansheng Liu; Martin G Belinsky; Gary D Kruh; James M Gallo
Journal:  J Pharm Biomed Anal       Date:  2007-01-12       Impact factor: 3.935

8.  Better effect of methotrexate on C-reactive protein during daily compared to weekly treatment in rheumatoid arthritis.

Authors:  P Seideman
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

9.  Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics.

Authors:  F Albertioni; B Flatø; P Seideman; O Beck; O Vinje; C Peterson; S Eksborg
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Facile Electrochemical Determination of Methotrexate (MTX) Using Glassy Carbon Electrode-Modified with Electronically Disordered NiO Nanostructures.

Authors:  Aftab A Khand; Saeed A Lakho; Aneela Tahira; Mohd Ubaidullah; Asma A Alothman; Khoulwod Aljadoa; Ayman Nafady; Zafar H Ibupoto
Journal:  Nanomaterials (Basel)       Date:  2021-05-12       Impact factor: 5.076

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.